Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
INTRODUCTION
The microtubules, formed by the polyerization of the cellular protein tubulin, play a crucial role in the cell division process hence any interference in the function of this protein can result in cell separation disruption and causes cellular death by apopto sis which can be used as a cancer treatment modality [1] . A number of the currently available anticancer drugs work by changing the extent of the microtubule polymer mass, either decreasing it for the tubulin polymerization inhibitors (such as vinka alkaloids [2] ) or increasing it for the tubulin poly merization promoters (such as the taxanes [3] ).
Halichondrin B is a natural product that was originally isolated from the Western Pacific sponge Halichondria okadai [4] and later from an Axinella sp. [5] . This compound was shown to bind to tubulin at a site close to the vinka site and inhibit tubulin polymerization [6] , but unlike other tubulin polymer ization inhibitors, halichondrin B inhibits the tubilin growth with no effect on microtubule shortening. It also sequesters tubulin into nonfunctional aggregates [7] .
Halichondrin B has also shown antiproliferative effects against a broad range of human cancer cell lines, including breast, prostate, melanoma, and colorectal [8] . Furthermore, it has been associated with tumor regression and elimination in a variety of well established human tumor xenograft models [9] thus it was an excellent candidate for clinical development. To overcome the major obstacle of clinical development of this product, compound supply, a research program at Eisai Re search Institute was initiated to develop a synthetically acces sible anticancer agent based on the halichondrin B skel eton. As a result of this program, the truncated halichondrin B ana log, eribulin (E7389), was discovered and showed activity in the preclinical models of diseases in which microtubule inhibitors already have a therapeutic role such as breast or ovarian cancer and also in other diseases in which they are less relevant such as colorectal cancer [911] .
PHARMACOLOGY
Two phase I trials of eribulin in solid malignancies were designed to assess the maximum tolerated dose (MDT), toxicity profile, preliminary anticancer activity and pharmacokinetics of two different intravenous administration methods; weekly (days 1, 8, and 15 of a 28days cycle) [12] and 3 weekly (a drip every 21 days) [13] methods.
ADMINISTRATION AND MTD
In the weekly study, 32 patients received doses ranging from 0. 25 , a dose level at which only one of six evaluable patients had DLT [13] .
PHARMACOKINETICS
In the weekly schedule, eribulin mesylate pharmacokinetics following a 1hour intravenous infusion, were linear and dose proportional over the dosing range of 0.25 to 1.4 mg/m 2 . Erib ulin exhibited consistent pharmacokinetic parameter estimates between the first and third intravenous doses administered on days 1 and 15 at each dose level. The plasma concentration time profile exhibited a rapid distribution phase with a mean distribution halflife of ~0.43 hours followed by a slower elimi nation phase with a halflife of 38.7 hours. The urinary excre tion route was thought to play a minor role in the elimination of eribulin. Overall urinary excretion of eribulin was minimal with 5% to 6% of the administered dose eliminated in urine over a 72hour period after a single dose [12] .
On the other hand, the 3 weekly schedule showed that the pharmacokinetic profile of eribulin was characterized by an extensive volume of distribution, a slowtomoderate clear ance, and a slow elimination, with only a small fraction of the drug (~7%) excreted unchanged in the urine. Eribulin exhib ited a plasma terminal halflife of ~2 days. Plasma area under the concentrationtime curve (AUC0∞) and maximum plasma concentration (Cmax) increased approximately linearly over the dose range studied; the dosenormalized Cmax and AUC0∞ values were consistent across dose levels with the exception of the 2 mg/m 2 dose level, where higher values were observed [13] .
Adverse events and clinical outcome
From both trials, neutropenia and fatigue were the predomi nant toxicities. Neutropenia occurred earlier in the 3 weekly schedule with neutropenic fevers occurring as early as day 7 of the first cycle. Alopecia was also reported in 33% of patient in the 3 weekly schedule. Eight patients in the weekly schedule and one in the 3 weekly had reported clinical manifestations of neuropathy. Hyponatremia and nausea were less frequently reported.
From both studies, two unconfirmed partial responses were observed (taxane refractory cervical and taxane naive non small cell lung cancers). Disease stabilisation was observed in 12 patients of the 3 weekly schedule (duration range, 47386 days) and 10 patients on the weekly schedule (duration range, 39234 days) [12, 13] .
ADVANCED PHASE TRIALS IN BREAST CANCER
Based on the phase I studies results, a number of advanced phase trials were conducted to evaluate the safety and efficacy of this drug. Three phase II trials of eribulin in chemotherapy pretreated advanced breast cancer patients using the weekly schedule (day 1 and 8 of 21 days cycle) were completed. In all these studies, eribulin showed a manageable tolerability pro file, with most of the common drugrelated adverse events being neutropenia, fatigue, alopecia, nausea, and anaemia and these were similar to the phase I trials findings. Eribulin was also associated with a low incidence of peripheral neuropathy overall and severe peripheral neuropathy was limited to grade 3 only [1416] . The objective response rates as reported in these studies were 11.5%, 14.1%, and 21.3%. Encouraged by the response rate and toxicity profile from previous studies, a large phase III trial has recently been completed. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) randomized patients with locally recur rent disease or metastatic breast cancer (MBC) previously treated with 2 to 5 prior chemotherapy regimens (including anthracyclines and taxanes) to eribulin (using phase II sched ule) or treatment of physicians' choice (TPC) [17] . This study has shown statistically significant increase in overall survival (hazard ratio, 0.81; 95% confidence interval, 0.660.99; p = 0.004) in the eribulin group (13.1 months) compared with TPC group (10.6 months). Grade 3/4 adverse events were reported in both arms. The common adverse events associated with eribulin were asthenia/fatigue (8.2% grade 3; 0.6% grade 4), neutropenia (21.1% grade 3; 24.1% grade 4) and peripheral neuropathy (7.8% grade 3; 0.4% grade 4), demonstrating a manageable tolerability profile for this agent when given as a monotherapy.
A second phase III study is underway to compare the efficacy and safety of eribulin with capecitabine. It contains important quality of life and pharmacokinetic correlates hence this will be the first study to provide a full analysis of the impact of eribulin upon the quality of life [18] .
In addition to breast cancer, phase II studies have been con ducted to assess the efficacy of eribulin in nonsmall cell lung cancer [19] , sarcoma [20] , ovarian cancer [21] , pancreatic [22] , head and neck [23] , and prostate cancers [24] .
ECONOMIC IMPACT/COST EFFECTIVENESS
Although eribulin mesylate is approved by the U.S. Food and Drug Administration for the treatment of patients with MBC who have previously received at least two chemothera peutic regimens for the treatment of metastatic disease [25] , In their application to NICE, the manufacturer estimated the gain per QALY. However, NICE review concluded that the most optimistic ICER for the overall intentiontotreat (ITT) group was £68,600 per QALY gained. Furthermore, given that the mean overall survival gain was 2.7 months from the over all ITT population, the Committee concluded that eribulin could not be considered a costeffective use of resources for National Health Service (NHS) use even if all of the criteria for being a lifeextending, endoflife treatment were met [26] .
CONCLUSION
Eribulin is a novel nontaxane microtubule dynamics inhibi tor that has demonstrated therapeutic activity in patients with solid tumors, particularly in heavily pretreated patients with MBC. Moreover, eribulin was shown to have a manageable toxicity and a modest incidence of neuropathy, which appears to be lower than with other microtubule inhibitor agents. Overall, eribulin represents a promising new treatment option as singleagent chemotherapy in patient's solid cancer and in particular, the chemotherapy pretreated breast cancer patients. On the other hand, the cost effectiveness of the drug remains a matter of a debate that will need to be taken in consideration for any future clinical evaluation of this drug.
